Cronos the first pot listing for Nasdaq stock exchange

Marijuana firm joins corporate giants in trading

The Nasdaq Stock Market will list its first cannabis shares on Tuesday, marking a key milestone for an industry that has been rejected by the Trump administration. Cronos Group Inc., which already trades on the TSX Venture Exchange, will be the first marijuana company on a major U. S. exchange — right alongside Nasdaq stocks such as Apple Inc., Microsoft Corp. and Starbucks Corp.

The listing could help expand the so- called Green Rush. U. S. investors who were previously uncomfortable or restricted from putting funds abroad or into over-the-counter stocks now have a mainstream option that has passed muster with the Securities and Exchange Commission.

“It’s very significant for the company and the whole industry,” Mike Gorenstein, founder and chief executive officer of Cronos, said in an interview. “It’s a huge moment — just shows the stigma is continuing to erode on cannabis.”

The move comes as the marijuana industry is expanding across the world. Uruguay has legalized cannabis federally for all adults, and Canada is expected to follow suit later this year. Germany is among about 30 countries that allow medicinal sales of the plant.

In the U. S., nine states and Washington, D.C., have legal recreational pot, and 29 states have legal medical cannabis. The American market alone is expected to reach US$ 50 billion by 2026, up from US$ 6 billion in 2016, according to i nvestment bank Cowen & Co.

Cronos is taking advantage of the international opportunity. The Toronto-based company produces and sells medical marijuana in Canada. It also ships its products to Germany, where they are distributed by G. PohlBoskamp GmbH. It will also retain its listing on the TSXV under the symbol “MJN.”

Cronos is also building a growing facility in partnership with a kibbutz in Israel and has received a license through a joint venture in Australia. Eventually, the company hopes to have a presence in the U.S. too, Gorenstein said, but not until it’s legal at the federal level.

Nasdaq’s approval came after Cronos spent six months doing preparatory work, leading up to an application for listing filed this year. The company had worked with Nasdaq to get approval for an over- thecounter listing last year.

The news helped send Cronos shares up as much as 11 per cent to US$9.83 on Monday. The stock had fallen 7.3 per cent this year through Friday’s close.

For Cronos, listing in the U. S. could open the doors to significant capital. It will also clear up confusion surrounding legal investment, Gorenstein said. About one of every three calls and discussions he’s had with American investors has focused on whether they can legally invest in the Canadian entity.

“A lot of U.S. investors still are unsure about the legality: There’s not a lot of awareness about the fact that it’s federally legal in Canada versus the U. S.,” he said. “By listing on Nasdaq, it will open up the opportunities for a lot of U. S. investors that otherwise were unsure — even on the institutional level.”

The confusion isn’t without cause. Cannabis is still federally illegal in the U.S. Attorney General Jeff Sessions in January rescinded the Obama- era protections that allowed state-legal industries to thrive.

Still, that illegality doesn’t prevent U. S. investors from putting money into foreign companies t hat operate legally in their respective countries, Gorenstein said.

Cronos was “l aser- f ocused” on making sure it was absolutely ready to conform to the U. S. SEC standards before filing i ts application to list on Nasdaq. That made the process relatively smooth.

“It was an exercise in checking everything we do and looking in the mirror and asking are there any gaps, because if we’re used as an example for other cannabis companies, we want to make sure that we’re setting the right example,” Gorenstein said.

Even before he founded Cronos, Gorenstein was no stranger to regulated industries. He started his career as an M& A lawyer, mainly working with alcohol and pharmaceutical companies.

There may be opportunities to team up with big companies in those spaces. Constellation Brands Inc., which sells Corona in the U. S., last year made a direct investment in Canopy Growth, one of Cronos’s competitors. A bigger partner can help capitalize on the industry’s enormous growth potential over the next few years.

“We’r e driving to go from zero to Pepsi in two years,” Gorenstein said. “That’s quite a bit to do without any help, so having partnerships — whether it’s an investor, distribution, joint development with alcohol and pharmaceutical companies — is very, very helpful.”

THE STIGMA IS CONTINUING TO ERODE ON CANNABIS.